U.S. Packaging Stock News

Gilead Sciences (GILD) is back in focus after releasing new Phase 3 data for Livdelzi in primary biliary cholangitis, with results showing stronger ALP normalization and a consistent safety profile in inadequately controlled patients. See our latest analysis for Gilead Sciences. The recent Livdelzi updates arrive while Gilead’s share price has eased in the short term, with the stock down over the past month and quarter, yet still showing a 6.22% year to date share price return and a 17.34% 1...

FuboTV stock performance snapshot FuboTV (FUBO) has seen its share price move lower recently, with the stock down about 6% over the past day, 17% over the past week, and 7% over the past month. Over the past 3 months, the stock has fallen around 32%, contributing to a year to date decline of roughly 69% and a total return drop of about 76% over the past year. See our latest analysis for FuboTV. Recent trading points to fading momentum, with the share price at about $9.54 after a sharp year to...

Lawsuit puts Atmos Energy’s safety practices in the spotlight A new wrongful death lawsuit tied to a fatal Dallas gas explosion has put Atmos Energy (ATO) under legal and public scrutiny, prompting investors to reassess safety risk, potential liability, and stock sentiment. See our latest analysis for Atmos Energy. Atmos Energy’s share price has eased in recent months, with a 1-month share price return of 5.88% and a 3-month share price return of 7.20% in decline, even as the latest lawsuit...

Bausch + Lomb (BLCO) is back in focus after announcing the U.S. launch of Blink Triple Care Preservative Free eye drops, a preservative free, multi dose dry eye product built on a clinically tested formula. See our latest analysis for Bausch + Lomb. The product launch lands at a time when Bausch + Lomb’s 1 year total shareholder return of 29.05% contrasts with a share price that is down 9.70% over 90 days and 6.76% year to date, suggesting recent momentum has cooled after a stronger year. If...

Southern (SO) is back in focus after reporting Q1 2026 earnings growth tied to heavier electricity demand from data centers and other large customers, along with a higher quarterly dividend that extends its 78 year payment record. See our latest analysis for Southern. At a share price of $92.60, Southern has seen a 7 day share price return of 4.01%, while the 90 day share price return is down 3.81%. This comes against a backdrop of fresh earnings, a new shelf registration filing, and ongoing...

Enact Holdings (ACT) stock overview Enact Holdings (ACT) has drawn investor attention after recent trading left the stock at a last close of US$41.79, following mixed short term returns across the past week, month and past 3 months. See our latest analysis for Enact Holdings. Recent trading has been choppy, with a 1-day share price return of 2.05% and a 7-day gain of 1.70%, while the 30-day share price return is down 5.11%. Even so, momentum over longer horizons looks firmer, with a year to...

Dianthus Therapeutics recently advanced its pipeline as the FDA eased safety requirements for claseprubart trials and granted the program orphan drug designation, while the company also prioritized its dual-mechanism autoimmune candidate DNTH212 with key clinical milestones scheduled through 2028. These regulatory and clinical developments, coupled with upcoming conference commentary, highlight how streamlined trial execution and targeted rare-disease positioning could reshape perceptions of...

Global inflation worries, rising bond yields and energy price swings are keeping markets on edge, which is why many investors are focusing on companies with strong balance sheets and efficient use of shareholder capital. The Solid Balance Sheet and Fundamentals screener highlights stocks with high return on equity, resilient past performance and prudent financial structures, qualities that can help support earnings quality when conditions are choppy. In this article, you will see 3 stocks...

Clinical data and regulatory milestones in focus Zenas BioPharma (ZBIO) stock is drawing attention after the company reported detailed Phase 3 INDIGO data for obexelimab in IgG4-Related Disease and advanced a Biologics License Application with the FDA. See our latest analysis for Zenas BioPharma. Despite the positive INDIGO data and recent Biologics License Application filing, Zenas BioPharma's share price has come under pressure, with the stock down 11.05% over 30 days and 49.36% year to...

Paycom Software (PAYC) is back in focus after a recent share price move, with the stock closing at US$137.62. For investors, the discussion now centers on how this level compares with its fundamentals. See our latest analysis for Paycom Software. The 1-day share price gain of 0.39% comes after a weaker patch, with the share price down 9.7% year to date and the 1-year total shareholder return declining 46.25%, suggesting momentum has been fading despite a modest 4.33% 90-day share price...

Teladoc Health (TDOC) is back in focus after expanding its virtual urgent care, dermatology, and nutrition services onto Walmart’s Better Care Services platform, giving the telehealth provider access to a broader retail customer base. See our latest analysis for Teladoc Health. At a share price of US$7.05, Teladoc Health has seen recent momentum cool, with a 7 day share price return down 10.87% and a 1 year total shareholder return down 4.73%. However, the 90 day share price return, up...

In recent weeks, Natera, Inc. has expanded its oncology and women’s health footprint through new collaborations using its Signatera MRD platform in metastatic colorectal cancer and refractory melanoma, launched a major clinical study for MRD-guided therapy de-escalation in early-stage breast cancer, enhanced its Panorama NIPT for low fetal fraction cases, and added two senior oncology experts to its board, while also disclosing an insider share sale by director Roelof Botha of 78,000 shares...

Inflation worries are back on center stage, with expectations for a 4.3% May CPI print, strong jobs data, higher Treasury yields, and rising talk of future Fed hikes all feeding into a bumpier market. For income focused investors, that mix can make high dividend stocks look both appealing and tricky, especially as energy prices stay elevated and volatility picks up. This article highlights three stocks from a High Dividend Yield Stocks screener that are directly exposed to these macro shifts,...

In May 2026, IDEXX Laboratories expanded its Fecal Dx antigen testing platform to include taeniid tapeworm detection, covering Taenia and Echinococcus species and automatically adding this capability at no extra cost for U.S. and Canadian reference lab customers. This enhancement broadens early, single-test detection of seven key intestinal parasite groups, reinforcing Fecal Dx’s role in addressing clinically important and zoonotic parasites for veterinarians worldwide. We’ll now examine how...

In early June 2026, Snowflake used its Summit 26 conference to unveil extensive AI-focused product upgrades, wider interoperability via Horizon Catalog and Apache Iceberg, and deeper partnerships with Amazon Web Services and Anthropic, alongside reporting first‑quarter sales of US$1,390.95 million and a reduced net loss of US$295.57 million. Together with customers such as Thomson Reuters and Sanofi and partners including Cognizant and Collibra, these launches show Snowflake positioning its...

Disc Medicine (IRON) has drawn fresh attention after presenting updated Phase 2 RALLY-MF data on DISC-0974 at ASCO, alongside launching a U.S. expanded access program for bitopertin in rare erythropoietic disorders. See our latest analysis for Disc Medicine. The updated trial data and expanded access program arrive after a softer patch for the stock, with the share price at US$67.0 and a year to date share price return down 15.29%. However, the 1 year total shareholder return of 30.30% and 3...

MPLX (MPLX) is back in focus after reporting first quarter 2026 earnings that fell short of estimates, as higher interest expenses, derivatives impacts, and depreciation weighed on results. See our latest analysis for MPLX. Despite the earnings miss, MPLX’s recent acquisitions in the Permian and progress on Marcellus projects have kept interest high. The stock has a 30 day share price return of 4.59% and a 5 year total shareholder return of 182.81%, suggesting long term momentum remains...

White Mountains Insurance Group (WTM) is back in focus after its 2026 Annual Investor Presentation, which outlined 2025 results, growth in book value per share, record capital deployment, and several portfolio transactions. See our latest analysis for White Mountains Insurance Group. The 1-year total shareholder return of 15.61% contrasts with a softer 90-day share price return, which fell 7.12%. This suggests momentum has cooled even as investors who stayed invested longer have seen stronger...

In late May 2026, Revolution Medicines reported detailed Phase 3 RASolute 302 data showing its oral RAS(ON) inhibitor daraxonrasib achieved statistically significant overall and progression-free survival benefits over standard chemotherapy in previously treated metastatic pancreatic cancer, with a manageable safety profile. The results, presented at ASCO 2026 and published in The New England Journal of Medicine, position daraxonrasib as a potential first-in-class option for RAS-driven...

In late May and early June 2026, Summit Therapeutics and partner Akeso reported new Phase II and Phase III ivonescimab data in colorectal and lung cancer at the ASCO Annual Meeting, while Summit also prepared to present a corporate update at Goldman Sachs’ Global Healthcare Conference. The combination of strong objective responses in first-line metastatic colorectal cancer and overall survival benefits in squamous non-small cell lung cancer highlights ivonescimab’s potential reach across...

Travelers Companies (TRV) has drawn fresh investor attention after recent trading left the stock near its last close of $303.25, which has prompted a closer look at its returns and fundamentals. See our latest analysis for Travelers Companies. The recent 3.35% 1 day share price return and 4.96% 7 day share price return suggest short term momentum is picking up for Travelers Companies, while its 1 year total shareholder return of 15.04% and 5 year total shareholder return of 117.16% point to a...

Acushnet Holdings (GOLF) is back on investors’ radar after a recent move in the share price, with the stock last closing at US$90. That puts fresh focus on how its golf focused business is currently valued. See our latest analysis for Acushnet Holdings. Recent trading has been mixed, with the 1 day share price return of 1.14% and year to date share price return of 9.61% set against a weaker 90 day share price return. However, the 1 year total shareholder return of 25.73% and 5 year total...

Exxon Mobil (XOM) is back in focus after crude prices jumped on renewed Middle East tensions and warnings about very low global oil inventories. The stock is moving alongside stronger earnings and expanding production. See our latest analysis for Exxon Mobil. Beyond the latest move in crude, Exxon Mobil’s 1 month share price return of 3.70% and 22.23% share price return year to date sit alongside a very large 5 year total shareholder return of 190.28%. This points to momentum that is still...

Chewy (CHWY) has been drawing attention after a period of weak share performance, with the stock down 10% over the past month and 19.5% over the past 3 months. See our latest analysis for Chewy. Those recent declines sit on top of a wider losing run, with the share price down 38.37% year to date and the 1 year total shareholder return falling 55.62%. This signals fading momentum as investors reassess Chewy’s growth profile and risk. If you are rethinking your watchlist after Chewy’s recent...